摘要
骨质疏松性骨折是一个重要的全球健康和经济问题。目前预测骨折的方法主要有基于骨密度的测量、骨小梁评分(TBS)和基于骨脆性临床风险因素的风险计算器(FRAX)的应用。尽管采用了这些方法,仍有许多骨折未得到早期预判。因此,目前的研究重点是识别新的因素,如骨代谢标志物(bone turnover markers,BTMs)用于风险计算。BTMs测定在多种骨骼疾病的诊断与鉴别诊断、骨质疏松疾病进展的监测、骨折风险预测和药物疗效评价等方面具有重要的临床应用价值。另外,BTMs在监测骨转换和骨折风险方面的潜在应用受到影响BTMs的生理和病理生理因素的限制,这局限性导致其临床指南的纳入仍然有限。
Osteoporosis fractures,also known as fragility fractures,continue to pose a significant global health and economic challenge.Current fracture prediction methods primarily rely on bone mineral density measurement,trabecular bone score(TBS),and the utilization of mathematical risk calculators like the Fracture Risk Assessment Tool(FRAX),based on clinical risk factors for bone fragility.Despite these approaches,a considerable number of bone fractures remain undetected in the early stages.Consequently,ongoing research is dedicated to identifying new factors,such as bone turnover markers(BTMs),to enhance risk assessment.The determination of BTMs holds crucial clinical value in diagnosing and differentiating various skeletal diseases,monitoring osteoporosis progression,stratifying fragility fracture risks,evaluating drug treatment responses,and ensuring adherence.However,the potential application of BTMs in monitoring bone turnover and fracture risk is constrained by physiological and pathophysiological factors affecting BTMs.This limitation,in turn,restricts their inclusion in clinical guidelines.
作者
邱敏丽
古洁若
QIU Min-li;GU Jie-ruo(Guangdong Provincial Clinical Medical Research Center of Immune Diseases,Department of Rheumatology and Immunology,the Third Affiliated Hospital of Sun Yat-sen University,Guangzhou 510630,Guangdong,China)
出处
《广东医学》
CAS
2024年第1期6-11,共6页
Guangdong Medical Journal
